Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

Inclusion Criteria:

1. Age \>18 years old, ECOG score 0 or 1;
2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
3. There was at least one measurable target lesion according to RECIST1.1 criteria;
4. Predicted survival time ≥12 weeks;
5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;
6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period;
7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.

Exclusion Criteria:

1. Severe abnormal liver and kidney function.
2. Pre-pregnancy, pregnant and lactating women.
3. Unable to lie flat for half an hour.
4. Refusal to be a clinical investigator.
5. Claustrophobia or other mental illness.
6. Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.